Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

It is widely accepted that glutamate-mediated neuronal hyperexcitation plays a causative
role in eliciting seizures. Among glutamate receptors, the roles of N-methyl-D-aspartate …

Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used
for various benign tumours associated with tuberous sclerosis complex. We assessed the …

Objective To update the 2004 American Academy of Neurology guideline for managing
treatment-resistant (TR) epilepsy with second-and third-generation antiepileptic drugs …

Abstract Background Brivaracetam (BRV), cenobamate (CNB), eslicarbazepine acetate
(ESL), lacosamide (LCM) and perampanel (PER) are antiseizure medications (ASMs) …

Objective: To assess efficacy and safety of adjunctive perampanel in patients with drug-
resistant, primary generalized tonic-clonic (PGTC) seizures in idiopathic generalized …

Antiepileptic drugs (AEDs) have many benefits but also many side effects, including
aggression, agitation, and irritability, in some patients with epilepsy. This article offers a …

Objective To evaluate the efficacy and safety of adjunctive cenobamate 200 mg/d in patients
with uncontrolled focal (partial-onset) seizures despite treatment with 1 to 3 antiepileptic …

Abstract Objective Oral cannabis extracts (OCEs) have been used in the treatment of
epilepsy; however, no studies demonstrate clear efficacy. We report on a cohort of pediatric …

Purpose: To assess the efficacy and safety of once‐daily doses of perampanel 8 and 12 mg
when added to 1–3 concomitantly administered, approved antiepileptic drugs (AEDs) in …